JoVE Logo

Oturum Aç

4.12 : Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.

Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action. This results in the activation of the receptor and subsequent signal transduction within the cell. Other agonists may bind to allosteric sites on the receptor, modifying the receptor's conformation and enhancing its response to the endogenous ligand.

Understanding the interaction of agonist drugs with receptors is crucial for drug development and personalized medicine. Studying the interaction between agonists and receptors helps unravel the mechanisms underlying drug action and improve therapeutic strategies. Based on the affinity of agonists for a receptor and their efficacy in producing a response, agonists can be classified as full, partial, or inverse agonists.

For example, phenylepinephrine, a full agonist for α1-adrenoceptors, activates receptors in the nasal mucosa, causing vasoconstriction that helps reduce edema and congestion from the nasal cavity.

On the other hand, various partial agonists are used clinically to help with smoking and opiate addiction. Examples include buprenorphine and varenicline, which occupy all opiate and nicotinic receptors. These drugs activate their respective receptors sufficiently enough to stop the brain from craving their full agonists, heroin and nicotine, helping in the prevention of smoking and heroin consumption.

Inverse agonists mainly act on the receptors that show constitutive activity without a ligand. A recently developed drug, pimavanserin, an inverse agonist of the 5-HT2A receptor, treats hallucinations associated with Parkinson's disease.

Etiketler

Drug receptor InteractionAgonistsBiological ResponseReceptor ActivationSignal TransductionTherapeutic ActionPersonalized MedicineDrug DevelopmentFull AgonistPartial AgonistInverse AgonistPhenylephrineBuprenorphineVarenicline5 HT2A Receptor

Bölümden 4:

article

Now Playing

4.12 : Drug-Receptor Interaction: Agonist

Farmakodinamik

2.3K Görüntüleme Sayısı

article

4.1 : İlaç Eyleminin İlkeleri

Farmakodinamik

5.7K Görüntüleme Sayısı

article

4.2 : İlaç Eylemi Hedefleri: Genel Bakış

Farmakodinamik

6.0K Görüntüleme Sayısı

article

4.3 : Sinyal İletimi: Genel Bakış

Farmakodinamik

8.2K Görüntüleme Sayısı

article

4.4 : Dönüştürücü Mekanizması: G proteinine bağlı reseptörler

Farmakodinamik

1.8K Görüntüleme Sayısı

article

4.5 : Ligand Kapılı İyon Kanalı Reseptörü: Geçit Mekanizması

Farmakodinamik

2.1K Görüntüleme Sayısı

article

4.6 : Dönüştürücü Mekanizması: Enzime Bağlı Reseptörler

Farmakodinamik

2.3K Görüntüleme Sayısı

article

4.7 : Dönüştürücü Mekanizması: Nükleer Reseptörler

Farmakodinamik

1.3K Görüntüleme Sayısı

article

4.8 : Doz-Yanıt İlişkisi: Genel Bakış

Farmakodinamik

2.9K Görüntüleme Sayısı

article

4.9 : Doz-Yanıt İlişkisi: Potens ve Etkinlik

Farmakodinamik

4.2K Görüntüleme Sayısı

article

4.10 : Doz-Yanıt İlişkisi: Seçicilik ve Özgüllük

Farmakodinamik

6.4K Görüntüleme Sayısı

article

4.11 : Terapötik İndeks

Farmakodinamik

4.1K Görüntüleme Sayısı

article

4.13 : İlaç-Reseptör Etkileşimi: Antagonist

Farmakodinamik

2.7K Görüntüleme Sayısı

article

4.14 : İlaçların Kombine Etkileri: Antagonizma

Farmakodinamik

8.3K Görüntüleme Sayısı

article

4.15 : İlaçların Kombine Etkileri: Sinerjizm

Farmakodinamik

3.7K Görüntüleme Sayısı

See More

JoVE Logo

Gizlilik

Kullanım Şartları

İlkeler

Araştırma

Eğitim

JoVE Hakkında

Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır